At a glance
ClinicalIndex Comparison RecordN/ACompleted· 25 enrolled
Drug / intervention
raltegravir +1 moredrug
Likely dose
raltegravir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy
In Brief
A clinical study evaluating raltegravir and efavirenz for HIV Infections and AIDS. Completed, enrolled 25 participants across 2 sites.
Detailed Summary
This research is being done to study how the immune system in the small intestine improves after taking antiretroviral (anti-HIV) medications. The main purpose is to measure the increase in the numbers of immune cells in the intestine to see if one type of HIV medication gives different results than other types of HIV medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, AIDS
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedApr 2008
Primary CompletionSep 2010
Study CompletionJul 2011
TodayJul 2026
First PostedApr 21, 2008
Enrollment StartMar 1, 2008
Primary CompletionSep 1, 2010
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.2 years ago
Interventions
raltegravirdrug
400mg tablet twice daily by mouth for nine months
efavirenzdrug
600mg capsule once daily by mouth without regard to food